Provider review
The Edit review
Two molecules, two prices, and the six-month rate shown next to each.
Nothing is struck through and nothing is labeled limited-time. The standing rate and the term rate sit side by side, so the annual cost of either choice takes about ten seconds to work out.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
How we’re funded. Some links here are affiliate links: start care through one and we may earn a commission, at no extra cost to you. Affiliate partners are listed first on our rankings — what we write about a provider is the same either way, and unflattering findings about one that pays us stay in. Full disclosure.
Price as published
The Edit
$209/mo sema · $309/mo tirz, six-month rates shown beside both
- Vs median
- $40/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The presentation here is unusually calm for this category. Two molecules, each with a standing monthly figure and its six-month rate printed alongside, and a short description of what each drug actually does — one hormone pathway or two — rather than a claim about how much weight it produces. Nothing is struck through, nothing carries a countdown, and the discount for committing longer is offered as an alternative rather than presented as the real price with the standing rate quietly withheld. That combination is rarer than it ought to be, and its practical effect is that a reader can cost a year on either molecule, at either commitment, straight off the page. What is missing is the dose. Neither figure has a milligram behind it, and both cards mention gradual titration without saying whether the price moves as the titration proceeds. For somebody intending to hold at a low dose, that is precisely the unanswered question — and it is the one thing the page would need to add to be genuinely useful to them rather than merely clear and honest, which it already is.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want the standing rate and the six-month rate visible together for both molecules.
- You want to know what each molecule does mechanically, not just what it is called.
- You are tired of struck-through figures and countdown labeling.
Look elsewhere if
- You are pricing a specific dose. No milligram sits behind either figure.
- You want to know whether the price rises as you titrate. The cards do not say.
- You want the compounding pharmacy named.
What it actually costs
Price as published
Compounded semaglutide $209/month, dropping to $178 on a six-month plan, and compounded tirzepatide $309/month dropping to $263 on the same term · both are once-weekly injections with gradual titration stated on the card · ★ the discounted term rate is printed beside the standing rate rather than replacing it, so a reader sees what they pay either way without having to start a checkout to find out · the two molecules are described by mechanism as well as name — a single GLP-1 pathway against the dual GLP-1 and GIP one — which is more explanation than most product cards carry · no dose is published behind either figure, so what the price covers as the titration proceeds is unstated
- Vs median
- $40/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate
- Market
- $59–$1300/mo is the full published spread in our ranking
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
152 of the 373 programs we track price a small dose this way. Both molecules carry a standing monthly figure with the six-month rate printed beside it, readable before intake. No low-dose product is offered and no dose sits behind either figure, so starting small means asking for less inside a standard plan at the standard price.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not included
- Labs
- Not required
- Pricing
- Varies by dose, plan or tier
- Price last updated
- August 2026
What it does well
- Shows the standing monthly rate and the six-month rate side by side for both molecules.
- Explains what each molecule does mechanically rather than only what it is called.
- No struck-through figures and no limited-time labeling anywhere.
Pharmacy, labs and oversight
The Edit dispenses through a Not named facility. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
3 of 4 published openly
What The Edit publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere we could find on its own pages.
- Published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
The presentation here is unusually calm for this category. Two molecules, each with a standing monthly figure and the six-month rate printed next to it, and a short description of what each drug actually does — one pathway or two — rather than a claim about how much weight it produces. Nothing is struck through, nothing is labeled limited-time, and the discount for committing is shown as an alternative rather than as the real price with the standing rate hidden. That combination is rarer than it should be, and it means a reader can work out the annual cost of either choice from the page in about ten seconds. What is missing is the dose. Neither figure has a milligram behind it, and both cards mention gradual titration without saying whether the price moves as the titration proceeds. For someone intending to hold at a low dose that is the unanswered question, and it is the one the page would need to answer to be genuinely useful to them rather than merely clear.
The honest cons
No dose is published behind either price.
- Both cards mention titration without saying whether the price changes as the dose rises.
- No compounding pharmacy is named.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
The Edit is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Where this sits
#191 of 373
Ordered with the companies that pay us first, and The Edit is not one of them. A disclosed partition, not a score.
Compare all 373 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What the evidence actually shows
- Microdosing tirzepatide
- The true annual cost of a plan
- Titration planner
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
From $194/mo
- Vs median
- $25/mo above the $169 median
- Market
- $59–$1300/mo across 242 of 373
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.